AZD-8835

1620576-64-8

C22H31N9O3

DMSO : 16 mg/mL (34.08 mM; Need ultrasonic and warming)

PI3K/Akt/mTOR

AZD8835 is a potent and selective inhibitor of PI3Kalpha and PI3Kdelta with IC₅₀s of 6.2 and 5.7 nM, respectively. IC50 & Target: IC50: 6.2 nM (PI3Kalpha), 431 nM (PI3Kbeta), 6 nM (PI3Kalpha-E545K), 5.8 nM (PI3Kalpha-H1047R), 5.7 nM (PI3Kdelta), 90 nM (PI3Kgamma)^[1] In Vitro: The selectivity profile of AZD8835 (Compound 25) among the class I PI3K isoforms is tested in enzyme and cell based assays. At the enzyme level, AZD8835 is a potent mixed inhibitor of PI3Kalpha (IC₅₀ 6.2 nM) and PI3Kdelta (IC₅₀ 5.7 nM), with selectivity against PI3Kbeta (IC₅₀ 431 nM) and PI3Kgamma (IC₅₀ 90 nM). AZD8835 is also a potent inhibitor of the commonly occurring PI3Kalpha mutants, PI3Kalpha- E545K (IC₅₀ 6 nM) and PI3Kalpha-H1047R (IC₅₀ 5.8 nM). In cell-based assays assessing the ability to inhibit Akt phosphorylation, AZD8835 is a potent inhibitor in cells sensitive to PI3Kalpha inhibition (IC₅₀ 57 nM in PIK3CA mutant human breast ductal carcinoma BT474 cell line) and in cells sensitive to PI3Kdelta inhibition (IC₅₀ 49 nM in Jeko-1 B cell line, but not to cells sensitive to PI3Kbeta inhibition (IC₅₀ 3.5 uM in PTEN null breast adenocarcinoma MDA-MB-468 cells) or to PI3Kgamma inhibition (IC₅₀ 530 nM in monocytic RAW264 cell line)^[1]. In Vivo: AZD8835 (Compound 25) displays good solubility, good permeability and low turnover in hepatocytes from various species. As expected from the in vitro data, low in vivo clearance associated with high bioavailability is seen in both rat and dog. AZD8835 shows high exposure following oral administration to SCID mice (AUC: 137 uM.h and C_max 34 uM at 50 mg/kg p.o.) and is selected for further in vivo evaluation. In a pharmacodynamic experiment following chronic oral dosing (25 mg/kg b.i.d. or 6 mg/kg b.i.d. of AZD8835) in nude mice bearing mutant H1047R PI3Kalpha SKOV-3 tumour xenografts, target modulation is assessed by measuring Akt phosphorylation levels at Ser473 at 30 minutes and 8 hours. At both doses, strong inhibition of Akt phosphorylation is observed at the 30 minute timepoint. At 8 hours, significant inhibition is still seen at the 25 mg/kg dose, whereas no inhibition is seen at the lower dose of 6 mg/kg, consistent with the lower plasma concentrations observed^[1].